Summary Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene regulation mechanisms research, and clinical oncology research services. Its other services comprise molecular oncology research, structure and membrane interaction research, genome stability DNA repair and maintenance, haematology research, oncology research, tumorimmunology research, mobile DNA research, cellular neurosciences research, and molecular muscle physiology research services. MDC focuses in the therapeutic areas of cardiovascular and metabolic diseases, cancer, nervous system disorders and medical systems biology. The centre collaborates with Leibniz Institute for Molecular Pharmacology and Charite Universitatsmedizin. MDC is headquartered at Berlin, Germany. Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a... Research Beam Model: Research Beam Product ID: 2114239 250 USD New
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : September   2017
  • Pages : 22
  • Publisher : GlobalData
 
 
 
Summary

Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene regulation mechanisms research, and clinical oncology research services. Its other services comprise molecular oncology research, structure and membrane interaction research, genome stability DNA repair and maintenance, haematology research, oncology research, tumorimmunology research, mobile DNA research, cellular neurosciences research, and molecular muscle physiology research services. MDC focuses in the therapeutic areas of cardiovascular and metabolic diseases, cancer, nervous system disorders and medical systems biology. The centre collaborates with Leibniz Institute for Molecular Pharmacology and Charite Universitatsmedizin. MDC is headquartered at Berlin, Germany.

Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 10
Licensing Agreements 12
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 12
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 13
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 14
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 15
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Key Competitors 16
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Key Employees 17
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Sep 02, 2016: Two MDC researchers win European Research Council Grants 19
Feb 19, 2016: Gene therapy: T cells target mutations to fight solid tumors 20
Product News 21
Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany's capital city of Berlin 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Key Facts 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Deals By Therapy Area, 2011 to YTD 2017 8
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 10
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 12
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 13
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 14
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 15
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Key Competitors 16
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Key Employees 17
List of Figures
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter